Blood stem cell transplants have been crucial in treating blood cancers, but recent advances in immune and targeted therapies have led to a decline in the use of these transplants, especially for lymphomas. Autologous transplants involve using a patient’s own stem cells, while allogeneic transplants use donor stem cells. The shift away from autologous transplants is due to the toxic nature of the treatment and the emergence of new therapies like CAR-T cell therapy. Allogeneic transplants are still used for certain cancers like acute myeloid leukemia. Research is ongoing to improve novel therapies and reduce the need for transplants in the future.
Source link
Bone marrow transplants becoming less common for blood cancer
